Bristol-Myers Squibb Co vs United Airlines Holdings Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.25 (market cap $129.94B), while United Airlines Holdings Inc trades at $127.64 (market cap $41.00B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.2× United Airlines Holdings Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while United Airlines Holdings Inc pays none. Which is the better fit depends on your goals.
| BMY | UAL | |
|---|---|---|
Market Cap | $129.94B | $41.00B |
Sector | Health | Industrials |
52-Week High | $65.89 | $136.11 |
52-Week Low | $42.60 | $85.21 |
Enterprise Value | $163.92B | $58.03B |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
United Airlines (UAL) trades at $123.76, down 4.48% today, but maintains a bullish technical signal with strong analyst support. The stock shows robust fundamentals, including a P/E of 11.83, net income margin of 5.56%, and three consecutive quarterly EPS beats. Revenue growth is steady, rising to $59.07B in 2025, with cash flow from operations at $8.43B. Recent news highlights CEO Scott Kirby's focus on innovation after merger attempts failed, while industry-wide fuel cost pressures are being managed.
Outlook remains positive with a consensus price target of $167.73, implying 35% upside. Opportunities include strong travel demand and operational efficiency, but risks involve volatile fuel prices, competitive pressures, and execution challenges. Wall Street sentiment is bullish with 66% buy ratings and no sell recommendations, supporting a favorable risk-reward profile for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →